Affordable Access

Publisher Website

Noninvasive Whole-Body Imaging of Phosphatidylethanolamine as a Cell Death Marker Using 99mTc-Duramycin During TNF-Induced SIRS.

  • Delvaeye, Tinneke1, 2, 3
  • Wyffels, Leonie4
  • Deleye, Steven5
  • Lemeire, Kelly1, 2
  • Gonçalves, Amanda1, 2, 6
  • Decrock, Elke3
  • Staelens, Steven5
  • Leybaert, Luc3
  • Vandenabeele, Peter1, 2
  • Krysko, Dmitri V7
  • 1 VIB Center for Inflammation Research, Ghent, Belgium. , (Belgium)
  • 2 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. , (Belgium)
  • 3 Physiology Group, Department of Basic Medical Sciences, Ghent University, Ghent, Belgium. , (Belgium)
  • 4 Molecular Imaging Center Antwerp, University of Antwerp, Wilrijk, Belgium [email protected] [email protected]. , (Belgium)
  • 5 Molecular Imaging Center Antwerp, University of Antwerp, Wilrijk, Belgium. , (Belgium)
  • 6 VIB BioImaging Core, Ghent, Belgium; and. , (Belgium)
  • 7 Anatomy and Embryology Group, Department of Basic Medical Sciences, Ghent University, Ghent, Belgium [email protected] [email protected]. , (Belgium)
Published Article
Publication Date
Jul 01, 2018
DOI: 10.2967/jnumed.117.205815
PMID: 29419481


Systemic inflammatory response syndrome (SIRS) is an inflammatory state affecting the whole body. It is associated with the presence of pro- and antiinflammatory cytokines in serum, including tumor necrosis factor (TNF). TNF has multiple effects and leads to cytokine production, leukocyte infiltration, and blood pressure reduction and coagulation, thereby contributing to tissue damage and organ failure. A sterile mouse model of sepsis, TNF-induced SIRS, was used to visualize the temporal and spatial distribution of damage in susceptible tissues during SIRS. For this, a radiopharmaceutical agent, 99mTc-duramycin, that binds to exposed phosphatidylethanolamine on dying cells was longitudinally visualized using SPECT/CT imaging. Methods: C57BL/6J mice were challenged with intravenous injections of murine TNF or vehicle, and necrostatin-1 was used to interfere with cell death. Two hours after vehicle or TNF treatment, mice received 99mTc-duramycin intravenously (35.44 ± 3.80 MBq). Static whole-body 99mTc-duramycin SPECT/CT imaging was performed 2, 4, and 6 h after tracer injection. Tracer uptake in different organs was quantified by volume-of-interest analysis using PMOD software and expressed as SUVmean After the last scan, ex vivo biodistribution was performed to validate the SPECT imaging data. Lastly, terminal deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining was performed to correlate the obtained results to cell death. Results: An increased 99mTc-duramycin uptake was detected in mice injected with TNF, when compared with control mice, in lungs (0.55 ± 0.1 vs. 0.34 ± 0.05), intestine (0.75 ± 0.13 vs. 0.56 ± 0.1), and liver (1.03 ± 0.14 vs. 0.64 ± 0.04) 4 h after TNF and remained significantly elevated until 8 h after TNF. The imaging results were consistent with ex vivo γ-counting results. Significantly increased levels of tissue damage were detected via TUNEL staining in the lungs and intestine of mice injected with TNF. Interestingly, necrostatin-1 pretreatment conferred protection against lethal SIRS and reduced the 99mTc-duramycin uptake in the lungs 8 h after TNF (SUV, 0.32 ± 0.1 vs. 0.51 ± 0.15). Conclusion: This study demonstrated that noninvasive 99mTc-duramycin SPECT imaging can be used to characterize temporal and spatial kinetics of injury and cell death in susceptible tissues during TNF-induced SIRS, making it useful for global, whole-body assessment of tissue damage during diseases associated with inflammation and injury. © 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Report this publication


Seen <100 times